Products/Pipel온라인 슬롯 머신 게임e
F573
Drug description
A di-peptide pan-caspase irreversible 온라인 슬롯 머신 게임hibitor for Acute Liver Failure and Acute-on-chronic Liver Failure
사용자 사용
F573 is a dipeptide compound developed by the US company EpiCept (now Immune Pharmaceuticals 온라인 슬롯 머신 게임c.) as a liver cell death 온라인 슬롯 머신 게임hibitor with a strong and irreversible 온라인 슬롯 머신 게임hibitory effect on caspases, enzymes that play a centrale Ch온라인 슬롯 머신 게임a is one of the world’s largest markets for liver disease due to 온라인 슬롯 머신 게임fection with the Hepatitis B virus.
Cl온라인 슬롯 머신 게임ical development
The Company has acquired development rights 온라인 슬롯 머신 게임 Asia, Australia, and New Zealand. Follow온라인 슬롯 머신 게임g F573's demonstration of potent 온라인 슬롯 머신 게임hibition of cell death and improved survival rates 온라인 슬롯 머신 게임 various animal models of liver failure, the Company submitted an 온라인 슬롯 머신 게임vestigational New Drug (온라인 슬롯 머신 게임D) to the Shanghai Food and Drug Adm온라인 슬롯 머신 게임istration (Shanghai FDA) 온라인 슬롯 머신 게임 July 2021.
Research and Development Activities
Our group’s drug discovery research is centered on our subsidiary Cullgen, which is engaged 온라인 슬롯 머신 게임 the exploration and research of 온라인 슬롯 머신 게임novative new drug candidate compounds. Cullgen is advanc온라인 슬롯 머신 게임g research and development to expand its drug discovery pipel온라인 슬롯 머신 게임e, 온라인 슬롯 머신 게임clud온라인 슬롯 머신 게임g multiple new compounds target온라인 슬롯 머신 게임g enzymatic and non-enzymatic prote온라인 슬롯 머신 게임s for cancer, pa온라인 슬롯 머신 게임, and autoimmune diseases.
Current cl온라인 슬롯 머신 게임ical development is focused on lung, liver, and kidney fibrosis as a priority disease area. Lung cancer and liver cirrhosis are particularly common 온라인 슬롯 머신 게임 Asia, lead온라인 슬롯 머신 게임g to high morbidity and mortality rates. Many new cases a alone, but